Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

INCB018424 in the Treatment of Cutaneous Lichen Planus

Trial Profile

INCB018424 in the Treatment of Cutaneous Lichen Planus

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Lichen planus
  • Focus Therapeutic Use

Most Recent Events

  • 12 Mar 2024 Results assessing the repurposed and optimized the modified Composite Assessment of Index Lesion Severity (mCAILS) for LP using data from NCT03697460 trial and validated the optimized lichen planus CAILS (lpCAILS) using data from NCT05188521 trial, presented at the American Academy of Dermatology annual Meeting 2024.
  • 01 Aug 2022 Results published in the Journal of Investigative Dermatology
  • 25 Apr 2021 Primary endpoint (lesion count) has been met, as per results presented at the American Academy of Dermatology Virtual Meeting Experience 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top